Trial design
This study was an open-label, parallel arm, randomized controlled trial with blinded end-points, which was conducted in a medical center in Iran. Recruitment occurred between January 25, 2020 and 2 February 2020. Follow-up continued until August 5, 2021.
Participants
Individuals were eligible to participate in the study after meeting all of the following inclusion criteria: 1) age ≥ 18 years; 2) receiving regular HD 3 times a week; 3) on HD for at least 1 year, 4) absence of a history of myocardial infarction within the past 3 months; 5) permission from their doctors to participate; and, 6) had capacity to provide informed consent to participate in the study. Individuals were excluded if they met any of the following exclusion criteria: 1) cardiac instability (angina, decompensated congestive heart failure, severe arteriovenous stenosis, uncontrolled arrhythmias, etc.); 2) active infection or acute medical illness; 3) hemodynamic instability; 4) labile glycemic control; 5) inability to exercise (e.g. lower extremity amputation with no prosthesis); 6) severe musculoskeletal pain at rest or with minimal activity; 7) inability to sit, stand or walk unassisted (walking device such as cane or walker allowed); or, 8) shortness of breath at rest or with activities of daily living (NYHA Class IV).
Trial procedures
After providing written informed consent, eligible patients received a baseline assessment. Data were collected on demographic characteristics (age, sex, and time on hemodialysis), primary cause of kidney failure, and comorbidities (atherosclerotic heart disease, congestive heart failure, cerebrovascular accident/transient ischemic attack, peripheral vascular disease, dysrhythmia, and other cardiac diseases, chronic obstructive pulmonary disease, gastrointestinal bleeding, liver disease, cancer, and diabetes). Comorbidities were quantified using Charlson comorbidity index (CCI) established for dialysis patients, which included the underlying cause of kidney failure, as well as 11 comorbidities [14].
Participants were then randomized in a 1:1 ratio to either the intervention group or control group. The randomization sequence was generated by a study biostatistician who was not otherwise involved in the study using a computer-generated random schedule (using Stata 16, Stata Crop, College Station, Tx). Allocation concealment was safeguarded through the use of sequentially numbered, sealed, opaque envelopes by a specified staff member who was not involved in the study.
Intervention
Subjects in the intervention group performed concurrent intradialytic exercise during the 2nd hour of dialysis (60-minute exercise sessions three times a week) for 6 months. The intervention was a combination of aerobic and resistance exercises. Workout time at the beginning was 30 minutes and gradually increased to 60 minutes. Exercises were individualized in a way that matched the level of physical fitness of participants (See Aditional File 1). Aerobic exercises consisted of continuously performed specified movements, such as moving legs back and forth, shoulder abduction and adduction (hand without fistula), flexing and extending the knee, internally and externally rotating the leg, and abducting and adducting the leg, in time with a played beat.
The rhythm of continuous movements was adjusted by the beats per minute of the music. This meant that participants had to coordinate the movements of their arms and legs with the beats per minute of the song being played to them. In this way, the speed and intensity of aerobic exercise was controlled by the rhythm. Resistance training was performed in a semi-recumbent position and included exercises for the upper and lower limbs as well as core strength exercises using body weight, weight cuffs, dumbbells, and elastic bands of varying intensity. Leg abduction, plantarflexion, dorsiflexion, straight-leg/bent knee raises, knee extension, and knee flexion were all part of the resistance training program.
Participants in the control group did not undertake any specific physical activity during dialysis. All participants were followed for 12 months.
All other pharmacological, dialysis, dietary and management protocols were identical for participants in both groups. All participants received normal bicarbonate hemodialysis, which was carried out three times a week for an average of 4 hours. Volumetric ultrafiltration control was available on all machines. The standard dialysate flow rate was 500 mL/min and blood flow rates were prescribed according to the participant’s needs. Automated methods were applied to perform dialyzer reuse uniformly.
Blood sampling
Baseline blood samples were collected one day before the start of the exercise session the day before a mid-week session. Exercise began at the mid-week dialysis session. After the end of the 36th session (end of the third month) and after the end of the 72nd session (end of the sixth month), subsequent blood samples were collected before the midweek dialysis session. The control group was assessed at the same time points. On a nondialysis day, blood samples were taken from the arterial needle after at least an 8-hour fast. Approximately 30 milliliters of blood were collected and centrifuged for 15 minutes at 20°C and 2500 g. Plasma was next pipetted into cryotubes and stored at -80°C in a freezer that was electronically monitored. All samples were measured in duplicate, in line with the manufacturers' suggested protocol, and within the manufacturer's specified range of acceptable variation and sensitivity.
Outcomes
The primary outcome measure was 1-year survival. Time frame started by ending the intervention (6th month). Information about the time and cause of death were extracted from participants’ medical records. This included information recorded in the CMS-2746 form.
Secondary outcome measures included changes in serum albumin (g/dL), hemoglobin (g/dL), hematocrit (%), red blood cell count (x106/µL ), serum calcium (mg/dL), serum phosphorous (mEq/L), and parathyroid hormone (PTH) (pg/mL) over time. Other secondary outcomes were physical function and nutritional status. These outcomes were evaluated at baseline, 3 months and 6 months.
Physical function was evaluated with the 6-minute walk test (6MWT), which is a functional examination of exercise capacity and was performed according to the American Thoracic Society guidelines [15]. In brief, the test was performed indoors on a 30m straight course. Participants were instructed to walk as fast as possible for 6 minutes. Walking aids were allowed and recorded. At the end of the 6-minute period, the distance was measured.
Nutritional status was assessed by Geriatric Nutritional Risk Index (GNRI), as reported by Bouillanne et al. [16] and modified for older patients, as reported by Yamada et al. [17]. The index was calculated as follows: GNRI = (14.89 albumin (g/dlL) + (41.7 x [body weight/ideal body weight]). When a participant's actual weight was greater than their ideal weight, the body weight/ideal body weight ratio was set to 1 by default. Instead of utilizing the Lorentz formula from the original GNRI equation to determine the ideal body weight, the value obtained from the participant's height and a body mass index of 22 was used [16 ]. Lower GNRI is a significant predictor of bone mineral disorders, cardiovascular events and all-cause mortality in dialysis patients [18–20].
Safety outcomes included all serious adverse events and adverse events.
Blinding
Due to the nature of the intervention, it was not feasible to blind participants or study staff.
However, outcome assessors and data analysts were blinded to participants’ treatment allocations.
Sample size
The sample size was calculated by NCSS PASS 16.0 software. The model was established according to the log-rank test of survival analysis (bilateral side), with α = 0.05 and power 1 – β = 0.8. Due to the fact that there had been no prior randomized controlled trials evaluating the effect of exercise on survival in dialysis patients, the results of a non-randomized study of the association of changes in physical activity with survival in dialysis patients were used to inform sample size calculations [21]. Assuming a hazard ratio of 0.25 between the intervention and control groups and a drop-out rate of 20%, 74 participants (37 per group) were required to provide 80% power.
Statistical analysis
Data are presented as frequency (percentage), mean ± standard deviation, or median and interquartile range, depending on data type and distribution. A detailed statistical analysis plan was prepared and completed prior to database lock. The primary outcome of survival was analyzed by Kaplan-Meier analysis and log rank test. Overall survival was calculated from the date of end of intervention to the date of death from any cause. Participants remaining alive were censored at the date of last follow-up. Cox regression model was constructed to evaluate the effect of intervention on survival rate. Secondary outcomes were evaluated using Repeated Measure ANOVA and the Friedman test. Statistical analyses were performed using IBM SPSS software 25. P values less than 0.05 were considered statistically significant.